Findings

What do systematic reviews say?

2,510 questions · 2,653 findings · 194 reviews · Gynaecology and Fertility

Sort:Best matchNewestHighest certainty Download CSV

No studies found 531 · 20%GRADE not reported 76 · 2.9%Very low 826 · 31.1%Low 855 · 32.2%Moderate 341 · 12.9%High 24 · 0.9%

GnRH‐a + estriol vs GnRH‐a ± placebo

Uterine bleeding · patients with uterine fibroids

The review found no eligible studies for this question.

1 finding from 1 review

Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

GnRH‐a + estriol vs GnRH‐a ± placebo

Severity of vasomotor symptoms · patients with uterine fibroids

The review found no eligible studies for this question.

1 finding from 1 review

Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

GnRH‐a + estriol vs GnRH‐a ± placebo

Rate of vasomotor symptoms ‐ · patients with uterine fibroids

The review found no eligible studies for this question.

1 finding from 1 review

Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

GnRH‐a + ipriflavone vs GnRH‐a ± placebo

Quality of life · patients with uterine fibroids

The review found no eligible studies for this question.

1 finding from 1 review

Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

GnRH‐a + ipriflavone vs GnRH‐a ± placebo

Bone density (SMD) ‐ · patients with uterine fibroids

1 finding from 1 review

Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 95 participants
Low

GnRH‐a + ipriflavone vs GnRH‐a ± placebo

Uterine size (cm3) ‐ · patients with uterine fibroids

The review found no eligible studies for this question.

1 finding from 1 review

Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

GnRH‐a + ipriflavone vs GnRH‐a ± placebo

Uterine bleeding · patients with uterine fibroids

The review found no eligible studies for this question.

1 finding from 1 review

Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

GnRH‐a + ipriflavone vs GnRH‐a ± placebo

Severity of vasomotor symptoms · patients with uterine fibroids

The review found no eligible studies for this question.

1 finding from 1 review

Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

GnRH‐a + medroxyprogesterone acetate vs GnRH‐a ± placebo

Uterine size (cm3) ‐ · patients with uterine fibroids

1 finding from 1 review

Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 32 participants
Low

GnRH‐a + ipriflavone vs GnRH‐a ± placebo

Rate of vasomotor symptoms ‐ · patients with uterine fibroids

GnRH‐a + ipriflavone showed no clear difference in rate of vasomotor symptoms ‐ compared with gnRH‐a ± placebo (low certainty).

1 finding from 1 review

Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
RR 0.67 [0.44, 1.02]
1 study · 95 participants
Low

GnRH‐a + conjugated estrogens vs GnRH‐a ± placebo

Reduction in uterine size · women with uterine fibroids

1 finding from 1 review

Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 27 participants
Very low

GnRH‐a + medroxyprogesterone acetate vs GnRH‐a ± placebo

Uterine bleeding · patients with uterine fibroids

The review found no eligible studies for this question.

1 finding from 1 review

Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

GnRH‐a + medroxyprogesterone acetate vs GnRH‐a ± placebo

Severity of vasomotor symptoms · patients with uterine fibroids

The review found no eligible studies for this question.

1 finding from 1 review

Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

GnRH‐a + medroxyprogesterone acetate vs GnRH‐a ± placebo

Rate of vasomotor symptoms ‐ · patients with uterine fibroids

GnRH‐a + medroxyprogesterone acetate may leads to lower rate of vasomotor symptoms ‐ compared with gnRH‐a ± placebo (low certainty).

1 finding from 1 review

Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
RR 0.13 [0.02, 0.84]
1 study · 16 participants
Low

GnRH‐a + tibolone vs GnRH‐a ± placebo

QoL · patients with uterine fibroids

1 finding from 1 review

Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 110 participants
Low

GnRH‐a + tibolone vs GnRH‐a ± placebo

Bone density (SMD) ‐ · patients with uterine fibroids

1 finding from 1 review

Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 160 participants
Moderate

GnRH‐a + tibolone vs GnRH‐a ± placebo

Uterine size (cm3) ‐ · patients with uterine fibroids

1 finding from 1 review

Add‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 365 participants
Moderate

DHEA vs placebo or control

QoL · Women in the peri‐ or postmenopausal phase

1 finding from 1 review

Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase 2015 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 287 participants
Moderate

DHEA vs HT

QoL · Women in the peri‐ or postmenopausal phase

The review found no eligible studies for this question.

2 findings from 1 review

Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

DHEA vs HT

Acne DHEA versus ET · Women in the peri‐ or postmenopausal phase

It is very uncertain whether DHEA changes acne DHEA versus ET compared with HT (very low certainty).

1 finding from 1 review

Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase 2015 · Cochrane Headline outcomes only
OR 17 [0.9, 320.37]
1 study · 50 participants
Very low